ATE412421T1 - Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie - Google Patents

Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie

Info

Publication number
ATE412421T1
ATE412421T1 AT03729360T AT03729360T ATE412421T1 AT E412421 T1 ATE412421 T1 AT E412421T1 AT 03729360 T AT03729360 T AT 03729360T AT 03729360 T AT03729360 T AT 03729360T AT E412421 T1 ATE412421 T1 AT E412421T1
Authority
AT
Austria
Prior art keywords
amylin
hypertriglyceridemia
dyslipidemia
treatment
derivatives
Prior art date
Application number
AT03729360T
Other languages
English (en)
Inventor
Orville Kolterman
Christian Weyer
David Maggs
Mark Fineman
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23362445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE412421(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE412421T1 publication Critical patent/ATE412421T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT03729360T 2002-01-08 2003-01-08 Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie ATE412421T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34712802P 2002-01-08 2002-01-08

Publications (1)

Publication Number Publication Date
ATE412421T1 true ATE412421T1 (de) 2008-11-15

Family

ID=23362445

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03729360T ATE412421T1 (de) 2002-01-08 2003-01-08 Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie

Country Status (9)

Country Link
US (1) US20030130177A1 (de)
EP (1) EP1474164B1 (de)
AT (1) ATE412421T1 (de)
AU (1) AU2003235742B2 (de)
CA (1) CA2475173A1 (de)
DE (1) DE60324387D1 (de)
ES (1) ES2316757T3 (de)
NZ (1) NZ534557A (de)
WO (1) WO2003057244A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534557A (en) * 2002-01-08 2007-10-26 Amylin Pharmaceuticals Inc Use of amylin or amylin agonists in the manufacture of a medicament for use in the treatment of dyslipidemia, wherein the medicament reduces post-prandial triglyceride levels
WO2006105527A2 (en) 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
WO2007014051A2 (en) * 2005-07-22 2007-02-01 Amylin Pharmaceuticals, Inc. Use of amylin and amylin agonists as cardioprotective or myoprotective agents
WO2007104789A2 (en) * 2006-03-15 2007-09-20 Novo Nordisk A/S Amylin derivatives
EP2036923A1 (de) * 2007-09-11 2009-03-18 Novo Nordisk A/S Verbesserte Derivate von Amylin
WO2010046357A1 (en) * 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives
CA2779088A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
CA2115159A1 (en) * 1991-08-08 1993-02-09 Jeffrey A. Bibbs Production of peptide amides
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
JP4798814B2 (ja) * 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
AU6585498A (en) * 1997-04-04 1998-10-30 Amylin Pharmaceuticals, Inc. Novel uncoupling protein and methods of use
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
CN1186017C (zh) * 2001-10-09 2005-01-26 陈立民 防治糖尿病、高脂血症和肥胖症的药物的配制方法
NZ534557A (en) * 2002-01-08 2007-10-26 Amylin Pharmaceuticals Inc Use of amylin or amylin agonists in the manufacture of a medicament for use in the treatment of dyslipidemia, wherein the medicament reduces post-prandial triglyceride levels

Also Published As

Publication number Publication date
AU2003235742B2 (en) 2008-08-07
AU2003235742A1 (en) 2003-07-24
ES2316757T3 (es) 2009-04-16
CA2475173A1 (en) 2003-07-17
DE60324387D1 (de) 2008-12-11
WO2003057244A3 (en) 2003-12-18
WO2003057244A2 (en) 2003-07-17
EP1474164A2 (de) 2004-11-10
NZ534557A (en) 2007-10-26
EP1474164B1 (de) 2008-10-29
US20030130177A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
DE60105547D1 (de) Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
CY1115361T1 (el) Στερεες μορφες περιλαμβανοντας (+)-2-[1-(3-αιθοξυ-4-μεθοξυφαινυλ)-2-μεθυλσουλφονυλαιθυλ]-4-ακετυλαμινοϊσοϊνδολιν-1,3-διονη, συνθεσεις εξ' αυτων, και χρησεις εξ' αυτων
DE69737592D1 (de) Mittel gegen juckreiz
NO20034056D0 (no) Proliferative sykdommer
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
EA200802213A1 (ru) Способы лечения заболеваний крови
NO20004872L (no) FremgangsmÕte for Õ stabilisere farmasøytiske sammensetninger ved spesiell anvendelse av en antioksidant
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
DE60010675D1 (de) Caspase inhibitoren und deren verwendung
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE60307749D1 (de) Verwendung von Flavonoid-Derivaten zur Behandlung von atopischem Ekzem
DK1237549T3 (da) Lipoxin A4 og dets analoger til behandling af törre öjne
ATE338036T1 (de) Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
ATE363531T1 (de) Claudin polypeptide
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE412421T1 (de) Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
REN Ceased due to non-payment of the annual fee